| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/08/1998 | WO1998000168A1 Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds |
| 01/08/1998 | WO1998000144A1 Fibrinogen receptor antagonist prodrugs |
| 01/08/1998 | WO1998000136A1 Virginiamycin mixture |
| 01/08/1998 | WO1998000135A1 Treatment of sepsis-induced acute renal failure and renal vasoconstriction and catecholamine-induced renal and mesenteric vasoconstriction |
| 01/08/1998 | WO1998000108A1 Proflavine composition and applicator |
| 01/08/1998 | WO1997041824A3 Antiangiogenic peptides derived from plasminogen |
| 01/08/1998 | DE19627376A1 Verwendung von Artischocken-(Cynara)-Extrakten Use of artichoke (Cynara) extracts |
| 01/08/1998 | CA2259298A1 Virginiamycin mixture |
| 01/08/1998 | CA2258513A1 Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds |
| 01/08/1998 | CA2257948A1 Antiarrhythmic combinations of selective iks antagonists with beta-adenergic blocking agents |
| 01/08/1998 | CA2257937A1 Fibrinogen receptor antagonist prodrugs |
| 01/07/1998 | EP0816502A2 Mur A-1, an UDP-N-acetylglucosamine enolpyruvyl-transferase from Streptococcus pneumoniae |
| 01/07/1998 | EP0816497A2 Human requiem polypeptide for apoptosis |
| 01/07/1998 | EP0815864A1 Semi-solid composition containing an antiflatulent agent |
| 01/07/1998 | EP0815860A2 Terfenadine carboxylate and the treatment of allergic disorders |
| 01/07/1998 | EP0815237A1 Threonyl-trna synthetase of staphylococcus aureus |
| 01/07/1998 | EP0815231A2 Use of neuronal apoptosis inhibitor protein (naip) |
| 01/07/1998 | EP0815228A2 Cellubrevin homologs |
| 01/07/1998 | EP0815227A1 HUMAN METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE mGluR6, NUCLEIC ACIDS ENCODING SAME AND USES THEREOF |
| 01/07/1998 | EP0815220A1 Human amine transporter |
| 01/07/1998 | EP0815137A1 Human g-protein chemokine receptor hdgnr10 |
| 01/07/1998 | EP0815133A1 Human stat4 |
| 01/07/1998 | EP0815116A1 Inhibition and modulation of gonadotropin-releasing hormone receptor activity |
| 01/07/1998 | EP0814845A1 Treatment of tumors by transduction with negative selective markers, application of interaction agents and subsequent radiation exposure |
| 01/07/1998 | EP0814842A1 Method for treating amyloidosis |
| 01/07/1998 | EP0814840A1 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent |
| 01/07/1998 | EP0814839A1 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid |
| 01/07/1998 | EP0814837A1 Use of g class immunoglobulins for the topical treatment of atopic dermatitis |
| 01/07/1998 | EP0814815A1 Poly(hydroxy acid)/polymer conjugates for skin applications |
| 01/07/1998 | EP0814813A2 Use of penciclovir for the treatment of human herpes-virus-8 |
| 01/07/1998 | EP0814812A1 Compositions comprising nicotynylalanine and an inhibitor of glycine conjugation or vitamin b6 |
| 01/07/1998 | EP0814810A1 Adenosine as a positive inotrop in the compromised heart |
| 01/07/1998 | EP0814806A1 Use of fused benzothiazoles as neuroprotectants |
| 01/07/1998 | EP0814803A2 Use of anti-oestrogens as male contraceptives |
| 01/07/1998 | EP0814801A2 Use of a pyruvate dehydrogenase activator for the treatment of ischaemia in limbs |
| 01/07/1998 | EP0814796A2 Use of a r-nsaid in a protective composition for the treatment of colorectal cancer |
| 01/07/1998 | EP0814793A1 Prilocaine and hydrofluorocarbon aerosol preparations |
| 01/07/1998 | EP0814789A1 Pharmaceutical compositions comprising monoamine oxidase b inhibitors |
| 01/07/1998 | EP0814785A1 Use of nitric oxide donors or nitric oxide inhibitors for regulating cervical dilatation and extensibility |
| 01/07/1998 | EP0814784A1 Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx |
| 01/07/1998 | EP0814775A1 Method and kit for preventing erectile dysfunction |
| 01/07/1998 | EP0814774A1 Reduction of adhesions using controlled delivery of active oxygen inhibitors |
| 01/06/1998 | US5705530 Side effect reduction; glaucoma treatment |
| 01/06/1998 | US5705521 Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors |
| 01/06/1998 | US5705506 Pharmaceutical compositions of alkylsulphonamides 5HT1 agonists for rectal administration |
| 01/06/1998 | US5705195 Drug delivery into blood for cardiovascular disorders |
| 01/06/1998 | US5705158 Kits with antileukocyte antibody conjugates |
| 01/02/1998 | DE19627340A1 Arzneimittel Drug |
| 12/31/1997 | WO1997049818A2 G-beta-gamma regulated phosphatidylinositol-3' kinase |
| 12/31/1997 | WO1997049805A2 Recognition molecules interacting specifically with the active site or cleft of a target molecule |
| 12/31/1997 | WO1997049420A1 Lectin compositions and uses thereof |
| 12/31/1997 | WO1997049411A1 Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv |
| 12/31/1997 | WO1997049410A1 Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv |
| 12/31/1997 | WO1997049409A1 Chelating agents and their metal chelates for treating free radicals induced conditions |
| 12/31/1997 | WO1997049407A1 Progestogen-anti-progestogen regimens |
| 12/31/1997 | WO1997049391A1 Methods for providing safe local anesthesia |
| 12/31/1997 | WO1997049390A1 Reduction of cardiotoxicity of an antitumor agent using manganese compound |
| 12/31/1997 | WO1997045528A3 Mammalian tolloid-like gene and protein |
| 12/31/1997 | WO1997044454A3 Human phospholipase inhibitor |
| 12/31/1997 | CN1168794A Method of reducing tissue damage associated with non-cardiac ischemia |
| 12/31/1997 | CA2262765A1 Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv |
| 12/31/1997 | CA2259150A1 Reduction of cardiotoxicity of an antitumor agent using manganese compound |
| 12/31/1997 | CA2258956A1 Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv |
| 12/31/1997 | CA2258299A1 Chelating agents and their metal chelates for treating free radicals induced conditions |
| 12/31/1997 | CA2255863A1 Progestogen-anti-progestogen regimens |
| 12/30/1997 | US5703122 Ascorbic acid compositions for reducing irritation of topically applied active ingredients |
| 12/30/1997 | US5703095 Prevention ferritin from releasing oxygen |
| 12/30/1997 | US5703088 Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses |
| 12/30/1997 | US5703073 Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| 12/30/1997 | US5703063 Phosphocholine conjugated steroid and carrier or diluent; increased bioavailability |
| 12/30/1997 | US5703058 Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
| 12/30/1997 | US5703051 Therapeutic uses of melanin |
| 12/30/1997 | US5702890 Inhibitors of alternative alleles of genes as a basis for cancer therapeutic agents |
| 12/30/1997 | US5702721 Multilayer |
| 12/30/1997 | US5702688 Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use |
| 12/30/1997 | CA2071629C Use of insulin sensitizing agents to treat hypertension |
| 12/29/1997 | EP0814158A2 Human C3a receptor variant; uses in diagnostics and therapeutics |
| 12/29/1997 | EP0813877A2 Method for treating congestive heart failure |
| 12/29/1997 | EP0813424A1 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate |
| 12/29/1997 | EP0813423A1 Composition to ameliorate osteolysis and metastasis |
| 12/29/1997 | EP0813418A2 Composition for treating skin conditions comprising an inhibitor of skin iso-phosphodiesterase |
| 12/29/1997 | EP0813414A1 Combination of bisphosphonates and growth hormone secretagogues |
| 12/29/1997 | EP0813408A1 Growth stimulating factors |
| 12/29/1997 | EP0813365A1 Immunoisolation |
| 12/29/1997 | EP0764026A4 Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders |
| 12/24/1997 | WO1997048822A1 Screening methods using microbial strain pools |
| 12/24/1997 | WO1997048804A2 Tie-2 receptor ligands (tie ligand-3; tie ligand-4) and their uses |
| 12/24/1997 | WO1997048803A1 Human protein kinase c inhibitor homolog |
| 12/24/1997 | WO1997048792A1 Transgenic non-human mammals with progressive neurologic disease |
| 12/24/1997 | WO1997048418A1 Improved method for treatment and diagnosis of il-5 mediated disorders |
| 12/24/1997 | WO1997048396A1 A method of treating liver disease and like indications with vasodilating agents |
| 12/24/1997 | WO1997048387A1 Device for topical treatment of acne and its method of manufacture |
| 12/24/1997 | WO1997040073A3 Biologically active protein (collagen fragment hf-coll-18/514cf) for inhibiting the growth of tumours and capillary profilerations |
| 12/24/1997 | WO1997034594A3 Use of allosteric haemoglobin modifier for treating solid tumors and inhibiting tumor metastases |
| 12/24/1997 | CN1168695A Inhibitor of stem cell proliferation and uses thereof |
| 12/24/1997 | CN1168631A Methods for treating resistant tumors |
| 12/24/1997 | CA2258696A1 A method of treating liver disease and like indications with vasodilating agents |
| 12/24/1997 | CA2258547A1 Screening methods using microbial strain pools |
| 12/24/1997 | CA2258526A1 Tie-2 receptor ligands (tie ligand-3; tie ligand-4) and their uses |
| 12/24/1997 | CA2258515A1 Improved method for treatment and diagnosis of il-5 mediated disorders |